Our details

This website is owned and operated by Inserm Transfert, This email address is being protected from spambots. You need JavaScript enabled to view it. (Phone number: +33 1 55 03 01 50, Address: 7 Rue Watt, 75013 Paris, France).

  • Design & Programming: ML-Com, France
  • Hosting: OVH,  140 quai du Sartel, 59100 Roubaix, tel.: +33 899 701 761 



Inserm Transfert maintains this website to enhance public access to information about Mirocals. Our goal is to keep this information timely and accurate. If errors are brought to our attention, we will try to correct them. However, Inserm Transfert accepts no responsibility or liability whatsoever with regard to the information on this site.

This information is:

  • of a general nature only and is not intended to address the specific circumstances of any particular individual or entity
  • not necessarily comprehensive, complete, accurate or up to date
  • sometimes linked to external sites over which Inserm Transfert have no control and for which Inserm Transfert assumes no responsibility

Mirocals is a research program. The content of this website is not intended to give medical diagnosis, treatment or medical advice.


Privacy policy

The site complies with the regulations on data processing, data files and individual liberties set out in the General Data Protection Regulation (EU Regulation 2016/679) (GDPR) and the French Data files and Individual Liberties defined by Law no. 78-17, as amended.


Copyright notice

All rights reserved.

This information may be freely used and copied for educational and other non-commercial purposes, provided that any reproduction of data be accompanied by an acknowledgement of Mirocals as the source (© Mirocals). 

This does not apply to the pages and images with explicitly reserved reproduction right: © followed by the right owner and the year of first circulation. Reproduction of the latter requires prior authorization from Mirocals.


Rare disease Day 2021 – 28 February 2021

Rare Disease Day takes place on the last day of February each year. The main objective of Rare Disease Day is to raise awareness amongst the general public and decision-makers about rare diseases such as ALS and their impact on patients' lives.

Take a look at the events happening around the world for rare disease day: https://www.rarediseaseday.org/

Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial

Results in this paper reveal that low dose IL-2 significantly increased the numbers of circulating Tregs, as predicted, and – importantly – improved their ability to control other immune cell responses that contribute to nerve cell damage.

Further information can be found at MND Research Blog

End of trial recruitment phase this autumn

The MIROCALS (Modifying Immune Response and Outcomes in ALS) Clinical Trial is still on-going, with recruitment continuing until the end of September 2019.

Read more

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 633413.